Performance of a novel eight‐color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia

Author:

Chen Xiao123,Chen Xia123,Zhao Sishu123,Shi Yu123,Zhang Ninghan123,Guo Zhen123,Qiao Chun123,Jin Huimin123,Zhu Liying123,Zhu Huayuan123,Li Jianyong123,Wu Yujie123ORCID

Affiliation:

1. Department of Hematology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Nanjing China

2. Key Laboratory of Hematology Nanjing Medical University Nanjing China

3. Department of Hematology, Collaborative Innovation Center for Cancer Personalized Medicine Nanjing China

Abstract

AbstractBackgroundMeasurable residual disease (MRD) is an important prognostic indicator of chronic lymphocytic leukemia (CLL). Different flow cytometric panels have been developed for the MRD assessment of CLL in Western countries; however, the application of these panels in China remains largely unexplored.MethodsOwing to the requirements for high accuracy, reproducibility, and comparability of MRD assessment in China, we investigated the performance of a flow cytometric approach (CD45‐ROR1 panel) to assess MRD in patients with CLL. The European Research Initiative on CLL (ERIC) eight‐color panel was used as the “gold standard.”ResultsThe sensitivity, specificity, and concordance rate of the CD45‐ROR1 panel in the MRD assessment of CLL were 100% (87/87), 88.5% (23/26), and 97.3% (110/113), respectively. Two of the three inconsistent samples were further verified using next‐generation sequencing. In addition, the MRD results obtained from the CD45‐ROR1 panel were positively associated with the ERIC eight‐color panel results for MRD assessment (R = 0.98, p < 0.0001). MRD detection at low levels (≤1.0%) demonstrated a smaller difference between the two methods (bias, −0.11; 95% CI, −0.90 to 0.68) than that at high levels (>1%). In the reproducibility assessment, the bias was smaller at three data points (within 24, 48, and 72 h) in the CD45‐ROR1 panel than in the ERIC eight‐color panel. Moreover, MRD levels detected using the CD45‐ROR1 panel for the same samples from different laboratories showed a strong statistical correlation (R = 0.99, p < 0.0001) with trivial interlaboratory variation (bias, 0.135; 95% CI, −0.439 to 0.709). In addition, the positivity rate of MRD in the bone marrow samples was higher than that in the peripheral blood samples.ConclusionsCollectively, this study demonstrated that the CD45‐ROR1 panel is a reliable method for MRD assessment of CLL with high sensitivity, reproducibility, and reliability.

Funder

National Natural Science Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3